This Is What Whales Are Betting On Pfizer
This Is What Whales Are Betting On Pfizer
Financial giants have made a conspicuous bullish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 20 unusual trades.
金融巨頭在輝瑞股票上採取了引人注目的看好行動。我們對輝瑞（紐交所:PFE）期權歷史的分析顯示，有20次不尋常的交易。
Delving into the details, we found 65% of traders were bullish, while 25% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $181,766, and 17 were calls, valued at $1,446,206.
深入分析後，我們發現65%的交易員看漲，而25%則呈現看淡趨勢。我們發現所有交易中有3次看跌交易，價值爲$181,766，有17次看漲交易，價值爲$1,446,206。
Projected Price Targets
預計價格目標
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $33.0 for Pfizer, spanning the last three months.
經過對成交量和未平倉量的評估，明顯的是主要市場操縱者正集中在輝瑞的$20.0到$33.0區間內，該區間跨越了過去三個月。
Analyzing Volume & Open Interest
分析成交量和未平倉合約
In terms of liquidity and interest, the mean open interest for Pfizer options trades today is 15393.88 with a total volume of 4,885.00.
就流動性和利益而言，輝瑞期權交易今天的平均未平倉量爲15393.88，總成交量爲4,885.00。
In the following chart, we are able to follow the development of volume and open interest of call and put options for Pfizer's big money trades within a strike price range of $20.0 to $33.0 over the last 30 days.
通過下面的圖表，我們能夠跟蹤輝瑞的看跌和看漲期權的成交量和未平倉量的發展，該圖表涵蓋了過去30天內的$20.0到$33.0的行權價格區間內的大手筆交易。
Pfizer 30-Day Option Volume & Interest Snapshot
輝瑞30天期權成交量快照和未平倉合約
Significant Options Trades Detected:
檢測到重大期權交易：
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | CALL | TRADE | BEARISH | 01/16/26 | $8.75 | $8.2 | $8.2 | $20.00 | $410.0K | 6.7K | 0 |
| PFE | CALL | SWEEP | BULLISH | 06/18/26 | $5.45 | $5.2 | $5.45 | $25.00 | $205.5K | 2.3K | 2 |
| PFE | CALL | SWEEP | BULLISH | 06/18/26 | $5.45 | $5.25 | $5.45 | $25.00 | $158.0K | 2.3K | 1.0K |
| PFE | CALL | TRADE | BULLISH | 01/17/25 | $1.26 | $1.22 | $1.26 | $30.00 | $126.0K | 48.7K | 80 |
| PFE | PUT | SWEEP | BEARISH | 10/18/24 | $5.45 | $5.35 | $5.45 | $33.00 | $104.6K | 21 | 0 |
| 標的 | 看跌/看漲 | 交易類型 | 情緒 | 到期日 | 賣盤 | 買盤 | 價格 | 執行價格 | 總交易價格 | 未平倉合約數量 | 成交量 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 輝瑞 | 看漲 | 交易 | 看淡 | 01/16/26 | $8.75 | $8.2 | $8.2 | $20.00 | $410.0K | 6.7千 | 0 |
| 輝瑞 | 看漲 | SWEEP | 看好 | 06/18/26 | $5.45 | $5.2 | $5.45 | $25.00 | $205.5K | 2.3K | 2 |
| 輝瑞 | 看漲 | SWEEP | 看好 | 06/18/26 | $5.45 | $5.25 | $5.45 | $25.00 | $158.0K | 2.3K | 1.0K |
| 輝瑞 | 看漲 | 交易 | 看好 | 01/17/25 | $1.26 | $1.22 | $1.26 | $30.00 | $126.0K | 48.7K | 80 |
| 輝瑞 | 看跌 | SWEEP | 看淡 | 10/18/24 | $5.45 | $5.35 | $5.45 | $33.00 | $104.6K | 21 | 0 |
About Pfizer
關於輝瑞
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
輝瑞是全球最大的製藥公司之一，年銷售額接近500億美元（不包括COVID-19產品銷售）。它歷史上銷售過許多種醫療保健產品和化學品，現在處方藥和疫苗佔據了銷售額的大部分。暢銷產品包括肺炎球菌疫苗Prevnar 13，癌症藥物Ibrance和心血管治療藥Eliquis。輝瑞在全球範圍內銷售這些產品，國際銷售佔總銷售額的近50%。其中，新興市場是主要貢獻者。
In light of the recent options history for Pfizer, it's now appropriate to focus on the company itself. We aim to explore its current performance.
鑑於輝瑞最近的期權歷史，現在適合關注公司本身。我們旨在探索其當前的業績。
Pfizer's Current Market Status
輝瑞當前的市場狀態
- With a trading volume of 9,819,447, the price of PFE is up by 0.63%, reaching $27.98.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 32 days from now.
- 輝瑞的交易量爲9,819,447，價格上漲了0.63%，達到了$27.98。
- 目前的RSI值表明該股票目前處於超買和超賣之間的中立狀態。
- 距離下一次盈利報告還有32天。
Professional Analyst Ratings for Pfizer
輝瑞的專業分析師評級
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $45.0.
在過去30天內，共有3位專業分析師對該股票發表了評論，設定了平均目標價格爲$45.0。
- Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.
- An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45.
- 出於擔憂，Cantor Fitzgerald的分析師將評級下調爲增持，設定新的目標價位爲45美元。
- 來自卡能特菲茨傑拉德的分析師將其行動評級下調至超配，目標價爲$45。
- 卡能特菲茨傑拉德的一位分析師將其行動評級下調至超配，目標價爲$45。
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.
期權交易存在更高的風險和潛在收益。精明的交易者通過不斷學習，調整策略，監視多個因子並密切關注市場走勢來管理這些風險。通過Benzinga Pro的實時警報，了解最新的輝瑞期權交易動態。
譯文內容由第三人軟體翻譯。